Jens-Peter Marschner, M.D.
As vice president of immunological programs, global clinical development unit oncology at Merck Serono, Dr. Jens-Peter Marschner oversees the development of active immunotherapeutics in all phases of clinical development including the lead project Stimuvax (L-BLP25). He studied medicine in Jena (Germany), obtained a doctorate in clinical pharmacology in 1991 from Johann-Wolfgang-Goethe-University in Frankfurt, and became a board certified specialist in clinical pharmacology in 1995.
During his more than 15 years career in the pharmaceutical industry, Dr. Marschner has worked with several companies where he was the medical leader for the development of mainly biological substances. At Merck KGaA, Darmstadt, Dr. Marschner was leading the cetuximab clinical team, later he became the leader of the Global Medical Affairs organization of Merck Serono before he took over the responsibility for the clinical development of immunological substances in oncology. Besides Dr. Marschner’s activity in the CIC, he is also a member of the European organization CIMT (Cancer Immunotherapy) and the American Society of Clinical Oncology (ASCO).